DDInter701 DDInter1652
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Etonogestrel {u} (Compound) resembles {v} (Compound) Nandrolone decanoate
Etonogestrel {u} (Compound) resembles {v} (Compound) Levonorgestrel
Etonogestrel {u} (Compound) binds {v} (Gene) PGR
Etonogestrel {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Etonogestrel {u} (Compound) causes {v} (Side Effect) Contraceptive device complication
Etonogestrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pioglitazone
Etonogestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Etonogestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Infliximab
Etonogestrel {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Etonogestrel (Compound) resembles Nandrolone decanoate (Compound)
Etonogestrel (Compound) resembles Levonorgestrel (Compound)
Etonogestrel (Compound) binds PGR (Gene)
Etonogestrel (Compound) is included by Progesterone Congeners (Pharmacologic Class)
Etonogestrel (Compound) causes Contraceptive device complication (Side Effect)
Etonogestrel may cause a minor interaction that can limit clinical effects when taken with Pioglitazone
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Etonogestrel may lead to a major life threatening interaction when taken with Brigatinib